News · 26 weeks46-21%
2026-03-012026-08-23
Mix2690d
- SEC Filings13(50%)
- Other13(50%)
Latest news
25 items- PRLōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100One year of work focused on one goal: manufacturing clinical material to enable once-weekly dosingLōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the Company's lead development candidate for osteoarthritis pain.The advancement of LT-100 to GMP production marks the next step in the Company's strategy to administer LT-100 (pure honeybee venom) as a single subcutaneous injection per visit – a patient-centric approach compared to the 15 intradermal injections per treatment used in prior efficacy trials."Earlier this year, we outline
- SECSEC Form DEFA14A filed by GlucoTrack Inc.DEFA14A - Glucotrack, Inc. (0001506983) (Filer)
- PRLōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of GeorgiaLōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai² Futures Lab™. The renewed collaboration expands Lōkahi’s growing nationwide network of academic institutions contributing to the identification and evaluation of underdeveloped, overlooked, or strategically deprioritized therapeutic assets. The program functions as a capital-efficient component of Lōkahi’s asset origination and evaluation process while providing students with direct experience addressing real-world biopharmaceutical business challenges. During its first year, the ai² Futures Lab™ engage
- SECGlucoTrack Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Achieves Key Compliance Milestone and Advances Strategic TransformationGlucotrack, Inc. (NASDAQ:GCTK) today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel has confirmed that Glucotrack has regained compliance with Nasdaq's stockholders' equity requirement. The decision represents an important milestone in the Company's efforts to strengthen its foundation and position for future growth. "This is an important milestone, but more significantly, it is an acknowledgment of the substantial progress we have made in repositioning Glucotrack for the future," said Erik Emerson, Chief Executive Officer of Glucotrack. "Over the past several months, we
- SECSEC Form DEF 14A filed by GlucoTrack Inc.DEF 14A - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRE.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for GlucotrackNEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor in connection with a $5.5 million financing for Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK). The financing was led by participating institutional investors and consisted of a $2.0 million equity financing, priced at $0.75 per unit, together with a $3.5 million follow-on investment in the form of convertible debt. Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, commented, "We are pleased to have advised Lōkahi Therapeutics and Glucotrack on this important finan
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Announces $5.5 Million FinancingIncludes $2.0 Million Equity Financing at $0.75 Per Unit, priced at a premium to the market, and $3.5 Million Follow-On Investment from Institutional Investors Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors, including a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in the form of convertible debt. The equity financing consists of units priced at $0.75 per unit, with each unit comprised of one share of common stock (or equivalent) and one five-year warrant with an exercise price of $1.50 per share.
- PRCORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a PipelineFutures Lab identified 45+ therapeutic opportunities on a $33,000 budget, expands to 13 university partners with 100% retention, and uncovers assets representing more than $500 million in prior industry investment. Please replace the release dated July 31, 2026, with the following corrected version due to multiple minor revisions. The updated release reads: LŌKAHI THERAPEUTICS™ AI² FUTURES LAB™ CHANGES HOW BIOPHARMA BUILDS A PIPELINE Futures Lab identified 45+ therapeutic opportunities on a $33,000 budget, expands to 13 university partners with 100% retention, and uncovers assets representing more than $500 million in prior industry investment. Glucotrack (NASDAQ:GCTK) today anno
- SECSEC Form PRE 14A filed by GlucoTrack Inc.PRE 14A - Glucotrack, Inc. (0001506983) (Filer)
- PRLōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a PipelineFutures Lab identified 45+ therapeutic opportunities on a $33,000 budget, expands to 12 university partners with 100% retention, and uncovers assets representing more than $500 million in prior industry investment. Glucotrack (NASDAQ:GCTK) today announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45 therapeutic opportunities on a budget of approximately $33,000 and advanced five into active company discussions. These assets represent more than $500 million in prior biopharmaceutical investment and include opportunities with human clinical data, pos
- SECGlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRLōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection AdministrationFDA Type C Meeting and Nonclinical Study Advance Strategy to Transition LT-100 from 15 Injections to One Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplified to a single subcutaneous (SC) injection per visit. During a Type C meeting with the U.S. Food and Drug Administration in May 2026, the Company discussed its proposed clinical strategy for LT-100. Following that meeting, Lōkahi completed a nonclinical minipig study designed to compare systemi
- SECAmendment: GlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K/A - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- SECSEC Form DEF 14A filed by GlucoTrack Inc.DEF 14A - Glucotrack, Inc. (0001506983) (Filer)
- PRE.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note FinancingNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor in the strategic business combination between Glucotrack, Inc. (NASDAQ:GCTK) and Lōkahi Therapeutics, and as exclusive placement agent for a concurrent convertible note financing of approximately $5.7 million to support the combined company's post-closing growth. The transaction establishes a publicly traded, capital-efficient healthcare platform, pairing Lōkahi Therapeutics' AI-driven asset sourcing and development capabilities with Glucotrack's Nasdaq listing to create a scalable framework f
- PRGlucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets InitiativesRUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi"), a clinical-stage biopharmaceutical company advancing innovative non-opioid biologic therapies and applying its proprietary ai²™ methodology to identify and develop high-value healthcare opportunities, today announced the completion of a bridge financing designed to support the Company's strategic growth objectives, including the continued advancement of the combined Glucotrack–Lōkahi platform and other anticipated capital markets activities. The bridge financing follows the completion of the s
- PRUPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public PlatformRUTHERFORD, N.J. and LA JOLLA, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. The transaction is structured such that Lōkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack’s public market platform to support long-term growth and access to capital. The combined organization integrates Lōkahi Therapeutics’ dual-engine model - its late-stage clinical development progr
- SECSEC Form 425 filed by GlucoTrack Inc.425 - Glucotrack, Inc. (0001506983) (Subject)
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public PlatformRUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. The transaction is structured such that Lōkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack’s public market platform to support long-term growth and access to capital. The combined organization integrates Lōkahi Therapeutics’ dual-engine model - its late-stage clinical development progr
- PRGlucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM PlatformRUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. ("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled "Methods and Systems for Continuously Monitoring the Glucose Level of a Patient." The allowed claims expand the intellectual property protecting the Company’s continuous blood glucose monitoring (CBGM) platform as it advances its multi-year, fully implantable CBGM system toward commercialization. The filing adds to
GCTK FAQ
5 questionsWhat does GlucoTrack Inc. do?
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.Where does GCTK stock trade?
GlucoTrack Inc. (GCTK) is listed on NASDAQ.What sector and industry is GCTK in?
GlucoTrack Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What companies are similar to GCTK?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare GCTK side-by-side with any of them on Quantisnow.How can I track GCTK on Quantisnow?
Quantisnow aggregates GlucoTrack Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GCTK to receive live email and push alerts on every new disclosure.